First edition · September 2026
Which standard actually binds you, which version you are on today, and what you may legitimately do differently
This guide does not summarise the pharmacopoeias — you already subscribe to those. It reconstructs the legal chains that make a compendial text binding, how you establish which version applies today, and the alternative-method regime in the European Union and the United States. 251 pages, 22 chapters across 6 Parts, 184 sources verified as at 14 September 2026, plus 14 editable tools ready to fill in.
251 pages · A4 · PDF22 chapters in 6 Parts14 editable tools6 appendices · 184 verified sourcesRegulatory cut-off 14/09/2026
The guide
Not a commentary on monographs, but a guide to the decision. Every chapter follows the same route — requirement, interpretation, risk, decision, action, evidence, demonstrability — and closes with the decisions no source makes on your behalf, collected one by one in an appendix.
The toolkit
14 editable tools: 8 Excel workbooks with working formulas, drop-down menus, conditional formatting and dashboards, and 6 Word templates already written to 70%, with section-by-section guidance, worked examples, an approval table and a revision history.
Updates included
Included for life. When Ph. Eur. Issue 13.1 becomes applicable, when BP 2027 takes legal effect, and when ICH Q3E and Q6(R1) leave draft status, you receive the updated edition at no further cost.
The three things this guide says that others do not
This is not a manual of analytical methods, and it reproduces no monograph. It is the book that answers three questions raised in the laboratory every week, and that almost no text answers in full.
The Ph. Eur. supplement model no longer exists. Since 2025 there is one edition per year, published in three Issues. The content in force today is that resulting from the Issues up to and including 12.3; 13.1 and 13.2 are already published but become applicable only in 2027. Every company procedure still citing “11th ed., Suppl. 11.8” points to a versioning model that is gone, and Chapter 6 shows how that cross-reference is rewritten.
The obligation is conformity to the standard, not execution of the method. The compendial method is the referee in the event of dispute, not the only procedure permitted. The European Union and the United States reach the same principle through entirely different legal chains — indirect in Europe, statutory in the United States — and neither chain transplants into the other. Chapters 2, 3, 9 and 10 walk through them one at a time.
No ICH text resolves the conflict between thresholds and monograph limits. Where a Q3A/Q3B threshold and a monograph limit diverge, no rule of precedence exists in the verified ICH texts. The guide documents that with the source and, in place of the missing rule, builds the decision method: what you verify first, how the choice is justified, and in what form the rationale still holds years later, when its author has left the company.
The 14 tools in the toolkit
Each tool comes out of the chapter that explains it, and exists in Italian and in English. None carries pre-loaded operational values: where a number would be the answer there is a placeholder, stating who decides, on what basis and where it is recorded — because a number pre-loaded into a template becomes the user’s default.
EXCELT-01 · Compendial version surveillance register
Text by text, which version applies today, which is published but not yet applicable, and which company documents depend on each one.
EXCELT-02 · Multi-region divergence matrix
Makes visible what actually diverges between the pharmacopoeias of the markets you serve, parameter by parameter and with two dates on every row.
EXCELT-03 · Reference standards register
Answers the question that always comes up here: does this lot still hold official status, and when was that last checked.
EXCELT-04 · Alternative method decision tree, EU / US
Establishes which regime your method sits in, with a separate outcome per jurisdiction: for a multi-market product the path is walked twice.
EXCELT-05 · Adjustment or modification? Chromatographic adjustments
Parameter by parameter, whether the deviation is an adjustment the general chapter permits or a modification of the method, always calculated from the compendial value.
EXCELT-06 · Compendial method verification plan
Governs the portfolio: how many compendial methods you run, which are covered, and why the uncovered ones are not.
EXCELT-07 · Impurity assessment: ICH threshold against monograph limit
Documents the divergence at the moment it is detected and preserves the rationale in a form that still holds years later.
EXCELT-08 · Compendial audit-readiness dashboard
Shows, before an inspection does, how much of the questioning your system actually covers and where the gaps sit.
WORDT-09 · SOP — Pharmacopoeial surveillance and revision management
Gives an owner, a workflow and a record to an activity spanning laboratory, quality and regulatory, and which, when it belongs to everyone, belongs to no one.
WORDT-10 · SOP — Qualification and management of reference standards
Two separate status-verification processes, one for the USP system and one for the Ph. Eur. system, because the mechanisms do not coincide.
WORDT-11 · Compendial method verification protocol
Selected performance characteristics with the rationale for the selection, and criteria fixed in advance: a protocol that leaves them open is not a protocol.
WORDT-12 · Alternative method justification rationale
The document missing from inherited method files, in a European and a US version: two markets need two rationales, not one translated.
WORDT-13 · Monograph revision impact assessment report
The downstream chain of every revision: what it touches, what was decided, by when, and with which amended documents and their effective dates.
WORDT-14 · Inspector response pack on compendial matters
Who answers for each macro-area, with which documents and where they live. It holds references, not copies.
You use it from tomorrow morning
| The situation | What you use |
|---|
| “Which version of the Ph. Eur. are we on, exactly?” | Chapter 6 + T-01: the Issue model, the end of supplements, and the register that watches text by text |
| One of your procedures still cites “Suppl. 11.8” | Chapters 5 and 6 + T-09: how the cross-reference is rewritten, and the SOP that stops it recurring |
| You want to run a method other than the monograph one, in the EU | Chapter 9 + T-04 and T-12: the three cumulative conditions, who the competent authority actually is, and the rationale that records them |
| The same method, but for the US market | Chapter 10 + T-04 and T-12: commitment in the filing, sole appropriateness of the official method, referee test and the 21 CFR duties that remain |
| The ICH threshold and the monograph limit do not agree | Chapters 15 and 19 + T-07: the conflict no text resolves, and how the decision is justified and preserved |
| You export to several regions on one specification | Chapter 16 + T-02: the divergence map is built before the strategy, not after it |
| The inspector asks whether that standard lot is still official | Chapter 17 + T-03 and T-10: lot status, date of the check, operator, and traceability back to the primary |
| You adjusted the chromatography and are unsure you could | Chapter 12 + T-05: always calculate from the value written in the pharmacopoeial procedure, then assess the combined effect |
| Inspection in two weeks | Chapters 21 and 22 + T-08 and T-14: the seven macro-areas, the open gaps, and who answers for each |
Regulatory rigour, declared line by line
Every regulatory statement carries exactly one label out of eight: [REQUIREMENT] for a binding legal obligation, [PHARMACOPOEIA] for a pharmacopoeial provision — which is not in itself a legal obligation and becomes one only through the legal chain of the jurisdiction — [GUIDANCE] for the expectation of a non-binding guidance, [GOOD PRACTICE] for settled industry practice with no text imposing it, [QRM] for a decision the organisation must take and justify, [GUIDEGXP] for an author’s interpretation declared as such, [DRAFT] for a public text with no regulatory force, and [NOT YET APPLICABLE] for an adopted text with a future effective date, always carrying that date. The distinction between the first two is the reason this volume exists.
The status of every source is verified as at 14 September 2026, and every text cited carries two separate dates: publication and application. The 184 sources are listed in an appendix with document, version, date, URL and verification status; where a source sits behind a subscription or returned a block on the date of consultation, the text says so and points to where the figure is read, instead of quoting it from memory.
No operational value is pre-loaded. Surveillance frequencies, validity periods, internal thresholds and acceptance criteria cannot be derived from a pharmacopoeia: in the guide and in the templates they appear as placeholders, with who decides, on what basis and where it is recorded. No table of compendial limits is reproduced, out of respect for the copyright of USP, EDQM, PMDA and the British Pharmacopoeia Commission — and because the number ages while the structure of the decision does not. The guide teaches where to read it and how to demonstrate that you did. Company, site and case-study data are openly fictional, and no real inspection finding is reported, quoted or paraphrased.
What is inside
Part I — Who binds you, and to what. The pharmacopoeias that matter: who writes them, what they contain and why they are not interchangeable. The European chain, from Annex I of Dir. 2001/83/EC to the method approved in the marketing authorisation. The US chain: FD&C Act §501(b), adulteration and the referee. Japan, the United Kingdom and Ph. Int., the other three chains. (Chapters 1–4)
Part II — Which version is in force today. Standard is not method, and version is not edition. Ph. Eur.: the Issue model and the end of supplements. USP–NF: six issues a year and the Accelerated Revisions that overtake them, with the CURRENTLY OFFICIAL marker as the only usable reference. Version surveillance: building the system and demonstrating it. (Chapters 5–8)
Part III — The alternative method. The three cumulative European conditions, and who the competent authority really is. The US rule: CPG 420.400 and the referee test. Verification, validation and transfer: three different operations that get confused. Permitted adjustments in chromatography: where adjustment ends and modification begins. (Chapters 9–12)
Part IV — When pharmacopoeias diverge. “Harmonised” does not mean “identical”: the four-member PDG. ICH Q4B and interchangeability, and what it actually permits. ICH against the monograph: the conflict no text resolves. Governing divergence across regions, with the three strategies and their costs. (Chapters 13–16)
Part V — The operational areas. Reference standards: current lots, secondary standards, and the traceability the inspector asks for. Dissolution and compendial methods, where the method is the product. Organic and elemental impurities and residual solvents. The shared perimeter: sterility, endotoxins, particulate matter. (Chapters 17–20)
Part VI — Demonstrating it in inspection. What the inspector looks at on compendial matters, across the seven macro-areas and in the form the questions are actually asked. The defensibility file, with five cases worked from start to close and linked to each tool. (Chapters 21–22)
Plus six appendices: the register of 184 verified sources with their verification status, the operational IT/EN glossary, the full register of decisions to be taken with who decides and where it is recorded, the datasheets for the fourteen tools, the comparative chapter map across pharmacopoeias, and the 2026–2028 regulatory calendar.
Read the preview before you buy
The free preview contains the Regulatory Status Box as at 14 September 2026, the legend of the eight labels, the full table of contents, the opening chapter and the overview of the fourteen tools. The preview exists in Italian and in English, as does the guide.
Specifications
| Format | PDF A4, 251 pages (EN edition) · 273 pages (IT edition) |
| Structure | 22 chapters in 6 Parts + 6 appendices |
| Toolkit | 14 editable tools (8 Excel, 6 Word), in Italian and in English |
| Sources | 184 verified sources, each with document, version, date, URL and verification status |
| Pharmacopoeias covered | USP–NF, Ph. Eur., JP, BP and Ph. Int., plus the PDG, ICH Q4B and the EU and US GMP framework |
| Languages | Guide, preview and toolkit exist in Italian and in English. Select the ITA or ENG variant before purchasing |
| Edition | First edition, September 2026 · regulatory cut-off 14/09/2026, verified against official sources |
| Delivery | Immediate download after purchase |
| Licence | Individual use, internal to the purchasing company |
Who it is for. QC Managers, QA Managers, senior QC laboratory analysts, Qualified Persons, Regulatory Affairs, method owners, auditors and consultants — and in particular anyone exporting to several regions, or about to. It is written for professionals: it does not explain what a pharmacopoeia is, it explains which one binds you, in which version, and how you demonstrate it months later.
Do you have an open compendial issue on a product or a market?
Describe the need and request support from a selected specialist.
Request specialist supportGuideGxP guides do not replace official regulations or compendial texts (USP–NF, Ph. Eur., JP, BP, Ph. Int., EMA, EU GMP, ICH, PIC/S, WHO, FDA, CFR): they are operational support tools, and the user remains responsible for applying the rules in force in their own corporate context and for verifying data against official sources on the date of use. Operational parameters have no universal value and must be defined and justified through risk management. GuideGxP is an independent publisher, not affiliated with any regulatory authority, pharmacopoeia or standards body. Digital product: no physical shipment.
